Objective We aimed to estimate the incidence of cerebral sinus and venous thrombosis
(CVT) within 1 month from first dose administration and the frequency of vaccine‐induced …

Objectives Development of safe and effective vaccines against coronavirus disease 2019
(COVID-19) remains the cornerstone of controlling this pandemic. However, there are …

Background and purpose Cerebral venous sinus thrombosis (CVST) has been described
after vaccination against SARS‐CoV‐2. The clinical characteristics of 213 post‐vaccination …

Introduction The common reported adverse effects of COVID-19 vaccination consist of the
injection site's local reaction followed by several non-specific flu-like symptoms. However …

The development of SARS-CoV-2 vaccines has raised several concerns regarding venous
thromboembolism, namely cerebral venous thrombosis. Although cerebral venous …

Recent reports from the Centers of Disease Control and the US Food and Drug
Administration identified 6 cases of CVST associated with thrombocytopenia in US patients …

Background There are concerns about a link between the ChAdOx1 nCoV-19 and Ad26.
COV2. S vaccines against COVID-19 and cerebral venous thrombosis (CVT) and other …

Background Several countries restricted the administration of ChAdOx1 to older age groups
in 2021 over safety concerns following case reports and observed versus expected analyses …

Objective Cerebral venous thrombosis (CVT) caused by vaccine‐induced immune
thrombotic thrombocytopenia (VITT) is a rare adverse effect of adenovirus‐based severe …

Background and purpose High mortality rates have been reported in patients with cerebral
venous sinus thrombosis (CVST) due to vaccine‐induced immune thrombotic …